Huang et al. found the expression level of CYP1A2 was lower in females than males, leading to higher systemic exposure of olanzapine in females, this may explain why female treated with olanzapine are more likely to develop AP. The gene discussed is CYP1A2; the disease is alkaline phosphatase measurement.